Ultimate CRISPR Stocks Guide

CRISPR equities provide near-unlimited investment opportunity for genetic editing experts.

Two scientists transformed the world in June 2012. Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier of Umea University presented a revolutionary scientific breakthrough: CRISPR-Cas9 genome editing. This accomplishment would pave the path for a new subsegment of biotech companies known as CRISPR stocks.

Why is this significant? The broad introduction and implementation of genetic editing in the 2020s will be one of the most transformational megatrends of our lifetimes.

And CRISPR stocks leveraged on this transformative megatrend will close the decade as among of Wall Street's most profitable investments.

And it all begins immediately.

In short, Doudna and Charpentier devised a time- and cost-efficient method for manipulating genetic materials and, in a sense, "playing God." Since the turn of the century, the developing area of genetic editing has been marked by constant innovation. Already, research in this sector has produced game-changing breakthroughs, such as the detection and treatment of vitamin A deficiency on a global scale.

In addition, CRISPR-Cas9 genetic editing technology will become a major disruptive force during the next decade. They will modify our reality in a literal sense.

They will aid in the treatment of sickness, the correction of genetic defects, the creation of sustainable biofuels, the engineering of pest-resistant crops, and the vast improvement of human existence.

It may seem complicated (and it is). However, in this section we will discuss CRISPR-Cas9 systems, the business of genetic editing, and why investors should care.

First things first then: What are CRISPR stocks exactly?

Humans have been obsessed with genetic tinkering and editing for decades.

The discovery of the double helix in the 1950s and the emergence of gene editing in the 1960s established the current direction of biology and genetics.

However, the concept of rewriting genes has never been realised in practise. Gene splicing and recombinant DNA were scientific advances, but they also presented an ethical risk.

Rather than breeding two animals and hoping for the best, CRISPR-Cas9 enables scientists to change entire genomes, resulting in previously unimaginable combinations.

This is the tale. Francisco Mojica was the first to develop the CRISPR principles in 1993 while working closely with bacteria. Yes, the greatest revolutionary scientific advancement of our lifetimes — and possibly ever — has been made by microbes.

Mojica's finding spawned a series of CRISPR-related developments, including the famed "glo-fish" pets. They utilised the naturally inherent fluorescence in fish to generate sub-generations that literally shine in the dark.

The CRISPR Innovation

By 2012, Doudna and Charpentier had made CRISPR's most significant advancement: employing "scissors," or CRISPR-Cas9 systems, to make precise, targeted cuts in DNA. These shears could be used to cut certain DNA strands and alter the genes within living creatures.

Doudna and Charpentier discovered in bacteria a naturally occurring genome editing method. It has the peculiar capacity to grab DNA fragments from invading viruses. The acquired DNA fragment is subsequently utilised to generate a new DNA segment known as a CRISPR array.

This CRISPR array is especially intended to identify the DNA of the invading virus. Therefore, if the invading virus infects the bacterium again, the array will recognise the virus' DNA. It immediately uses a Cas9 enzyme to "sever" the invading DNA fragment, rendering the virus ineffective.

It is a brilliant defence mechanism bacteria deploy to repel invading viruses.

Doudna and Charpentier pondered whether or not they might recreate this great approach of genome editing in bacteria and use it elsewhere.

Indeed, they did so.

Essentially, the two scientists developed a method to create CRISPR arrays linked with a specific DNA target sequence in a genome. This array is subsequently injected into the genome, where it connects to the desired sequence. Then, a Cas9 enzyme is used to cleave the DNA at the desired spot.

Once the DNA is cut, researchers are free to insert, remove, and/or modify genetic information in the DNA sequence.

Potential Consequences of Genetic Editing. If this sounds significant, it is because it is.

The potential ramifications of genetic editing at scale are limitless.

Since Doudna and Charpentier's groundbreaking discovery, genetic engineering has entered a new age. Now, some of the brightest minds in the most prominent laboratories are utilising CRISPR-Cas9 to potentially alter the course of history.

Currently, research is conducted to advance the use of CRISPR-Cas9 to treat diseases such as cystic fibrosis, cancer, and sickle cell anaemia. CRISPR has the capability to erase inherited blindness. Utilized to increase biofuel tolerance (and in turn, create more sustainable biofuels). And scientists are also utilising it to develop crops with enhanced pest- and disease-resistance.

In other words, CRISPR-Cas9 enables us to construct a future devoid of disease, food shortages, and depletion of natural resources.

Consequently, I reiterate: the potential consequences of CRISPR-Cas9 genome editing systems are limitless. While significant, this should not be unexpected. Ultimately, every living creature on earth has DNA. Therefore, a flawless CRISPR-Cas9 system could hypothetically alter anything.

But if this is true, why aren't CRISPR-Cas9 systems ubiquitous? Why has cancer not yet been cured? Why do crops continue to perish from pests and disease?

In fact, CRISPR-Cas9 technologies were first introduced eight years ago. Where are the results in the actual world?

Answer: Obscured by an impassable mound of genetic data.

And this is where the second phase comes into play.

CRISPR Stocks and the Problem of Genetic Data

CRISPR-Cas9 gene editing is a difficult field of study. Ultimately, you are severing DNA sequences. And to accomplish so without causing unintended side effects, significant precision is required.

Imagine rearranging The Wasteland by T.S. Elliot. A single alteration to the structure of the prose would completely alter the work's meaning and render it ineffective. The removal of one stanza affects not only the following and preceding stanzas, but the entire composition.

The same holds true in terms of splicing DNA sequences. If scientists are to cut a DNA sequence precisely and successfully, they must have a complete understanding of the sequence. What is inside? What is its neighbour? What are we destroying? What will happen if we eliminate this genetic material? Will there be negative effects if we carry out this procedure? How do we manage these adverse effects?

It differs from cutting paper. A botched genetic editing procedure could result in severe unfavourable side effects.

Detailed Analysis of the Data

While researchers are no less confident in their work than in the past, they can now be more accurate and advance science more rapidly.

Achieving certainty with data. If scientists have all the DNA sequencing data on all genetic organisms in the world, they will know precisely where and when to cut, what to inject, and how to patch everything up after they're finished.

Unfortunately, this is a huge "if," which has proven to be a formidable barrier to the efficient administration of CRISPR-Cas9 systems. In the end, this has mostly kept genetic editing in the "hypothetical testing" phase.

The human genome has more than 3 billion base pairs and 20,000 genes. And individuals are unique, as are animals and crops. Everything is unique.

You have the idea. The quantity of genetic information in the planet is unprecedented. Until recently, scientists lacked the means to efficiently sort and interpret all of this data.

Artificial intelligence (AI) then arrived at the gathering.

The Financial Value of CRISPR Stocks

Make no mistake. Over the next decade, this transformation toward tangible genetic editing will occur on a large scale. As this occurs, humans will make enormous strides in healing disease, enhancing health, and enhancing food safety. The list is exhaustive.

As CRISPR stocks become more "mainstream," this tectonic change has tremendous economic ramifications.

On the front of sickness, scientists have found more than 6,000 genetic abnormalities. They impact around 1 out of every 50 people worldwide. CRISPR-Cas9 genome editing tools have the potential to heal all of these conditions. In doing so, they will completely replace the $50 billion industry for drugs to treat genetic abnormalities. Consequently, the addressable market for genetic editing in human illness treatment alone is worth more than $50 billion.

In the meantime, market research firms estimate that the global biofuels business is already worth more than $100 billion and will reach $150 billion during the next four to five years.

Genetic modification could be the key to unlocking even greater value in this $150 billion and quickly expanding sector.

In addition, the global crop protection industry exceeds $60 billion. Also, genetic engineering could turn this entire market on its head.

The total addressable market for genetic editing tools is therefore far in excess of $200 billion.

However, the market capitalization of the majority of genetic editing companies today is less than $5 billion. And this gap between current valuations and future economic potential represents your opportunity.